Shares of Cigna Group declined 3.2% post-earnings, as investor disappointment centered on the company's cautious full-year 2026 outlook despite management highlighting raised adjusted EPS guidance. The market response suggests concerns about decelerating growth, possibly tied to margin pressures or uncertainty in addressing rising healthcare costs.
- Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79.
- The company slightly raised its full-year 2026 adjusted EPS outlook to at least $30.35.
- Management emphasized efforts to address affordability and streamline healthcare access, including a 15% reduction in prior authorizations.
- A new rebate-free pharmacy service model (“Signature”) was introduced, targeting price transparency and reduced brand drug costs.
- The CEO transition to Brian Evanko is on track for July 1, with continued focus on cost control and innovation amid ongoing industry pressures.
Community Discussion